HePlatinum Pharmaceutical-B (02142) is included in the Hang Seng Composite Index and is expected to become the Hong Kong Stock Exchange Standard

Zhitong Finance App learned that on August 21, 2026, Hang Seng Index Company announced the results of the Hang Seng Index series of quarterly reviews up to June 30, 2026. Among them, Heplatinum Pharmaceutical-B (02142) was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Heplatinum Pharmaceutical-B (02142) may be transferred to the Hong Kong Stock Connect because it meets a range of standards including market value, liquidity, etc.

Hebo Pharmaceutical announced that the clinical trial application for HBM7004 as a new drug for the treatment of advanced solid tumors has been approved by the State Drug Administration. This is another important development since the company announced on May 8, 2026 that it obtained approval from the US FDA for its IND application.

According to reports, HBM7004 is a novel b7H4xCD3 bispecific antibody developed from the Group's proprietary HBICE® platform to provide differentiated solutions for cancer immunotherapy in terms of efficacy and safety. The development of the HBM7004 further highlights the flexible applicability and plug-and-play advantages of the HBICE® platform.